Dyadic's collaboration with Janssen terminated; wind-down by Dec 31, 2023

DYADIC INTERNATIONAL INC

Janssen Biotech provided written notice on Oct 2, 2023 to terminate the Research, License, and Collaboration Agreement with Dyadic.
Collaboration effective end date is December 31, 2023.
Agreement originally entered Dec 16, 2021 for manufacture of therapeutic proteins using Dyadic's C1 platform.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DYADIC INTERNATIONAL INC terminated Research, License, and Collaboration Agreement with Janssen Biotech, Inc. (effective 2023-12-31).

Action: termination
Agreement: license
Counterparty: Janssen Biotech, Inc.
Effective: 2023-12-31

Exact text from the filing

Pursuant to Section 12.3 of the Agreement, on October 2, 2023, Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of December 31, 2023.

View on SEC.gov

242 material agreements filed in the last 30 days. Browse all material agreements →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-027854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.